[Form 4] Centessa Pharmaceuticals plc American Insider Trading Activity

Rhea-AI Filing Summary

WEC Energy Group (NYSE: WEC) filed a Form 144 indicating a proposed sale of 2,500 common shares (≈0.0008 % of the 321.9 million shares outstanding) through Morgan Stanley Smith Barney. The shares, valued at $276,362.50 based on market price, were acquired on 08/01/2025 via the exercise of employee stock options under a registered plan and are scheduled to be sold on or after 08/01/2025 on the NYSE. No other sales were reported in the past three months. The filer certifies there is no undisclosed material adverse information about WEC.

Positive

• Transparent disclosure via timely Form 144 filing supports governance best practices.
• Sale size is immaterial (<0.001 % of shares outstanding), limiting dilution or market impact.

Negative

• Insider selling, even if small, can be perceived as a soft negative signal.

Insights

Equity Analyst

TL;DR: Minor insider sale; negligible dilution; neutral impact.

The notice covers only 2,500 shares, worth roughly $0.28 million, versus WEC’s multibillion-dollar market cap. Such routine option-related sales are common for executives diversifying personal holdings. With no concurrent negative news and no recent selling history, the filing is immaterial to valuation. Investors should monitor cumulative insider activity, but this single transaction does not alter the investment thesis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Accardi Mario Alberto

(Last) (First) (Middle)

C/O CENTESSA PHARMACEUTICALS PLC

3RD FL., 1 ASHLEY RD, ALTRINCHAM

(Street)

CHESHIRE X0 WA14 2DT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Orexin Program

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	08/01/2025		F		597(2)	D	$17.17	207,566	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.

Remarks:

	/s/ Richard Menziuso, attorney-in-fact	08/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many WEC shares are being sold under this Form 144?

The filing covers 2,500 common shares.

What is the dollar value of the proposed WEC share sale?

Aggregate market value is $276,362.50.

When is the anticipated sale date for the WEC shares?

Approximately 08/01/2025 on the NYSE.

How significant is this sale relative to WEC's total shares outstanding?

The sale represents about 0.0008 % of the 321,866,395 shares outstanding.

What was the source of the shares being sold?

They were obtained via option exercise under a registered plan on 08/01/2025.

Were any WEC shares sold by this filer in the prior three months?

No; the filing states "Nothing to Report" for the past three months.